Amazon has been in preliminary discussions with Mylan and Sandoz, two giant manufacturers of generic drugs. Speculation about the generic drug trade being “Amazon’d” has negatively impacted stock in all phases of the complex industry. If Amazon is considering picking up distribution of drugs from pharmaceutical manufacturers to pharmacies, then the negotiations would only impact distributors like McKesson, AmerisourceBergen, and Cardinal Health. If Amazon wants to retail the drugs directly to consumers, then the move would be more disruptive. While the conversations have not been made public, Sandoz has indicated that any deal with Amazon is not expected to significantly impact its business. Executives of pharmaceutical companies Allergan and Pfizer have said they welcome improvements Amazon can make to distribution, but other industry leaders consider the market too complex and regulated for their platform.